Check out the companies making headlines after the bell Thursday:
Gilead Sciences shares dropped more than 6 percent as the company posted earnings of $3.03 a share ex-items on just shy of $8 billion in revenue. Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
During the first quarter, Gilead's hepatitis C drugs Harvoni and Sovaldi saw $3.02 billion and $1.28 billion in sales, respectively. Analysts had expected $3.13 billion and $1.37 billion in sales, according to a consensus estimate from FactSet.
Amazon shares surged 12 percent after the company posted quarterly that were significantly better than Wall Street expectations. The online commerce giant reported earnings of $1.07 a share on $29.13 billion in revenue. Analysts had expected the company to post earnings of 58 cents a share on $27.98 billion, according to a consensus estimate from Thomson Reuters.
For the second quarter, Amazon expects net sales of $28 billion to $30.5 billion, which would mark 21 to 32 percent growth from the previous year. Wall Street expected $28.32 billion in revenue, according to StreetAccount.